5-(N-t-butoxycarbonylindol-2-yl)-2-methyl-1-(tetrahydropyran-4-yl)benzimidazole → HCID 67497943, 화합물
반응식
C(OC([N:8]1[C:16]2[C:11](=[CH:12][CH:13]=[CH:14][CH:15]=2)[CH:10]=[C:9]1[C:17]1[CH:32]=[CH:31][C:20]2[N:21]([CH:25]3[CH2:30][CH2:29][O:28][CH2:27][CH2:26]3)[C:22]([CH3:24])=[N:23][C:19]=2[CH:18]=1)=O)(C)(C)C>Cl>[NH:8]1[C:16]2[C:11](=[CH:12][CH:13]=[CH:14][CH:15]=2)[CH:10]=[C:9]1[C:17]1[CH:32]=[CH:31][C:20]2[N:21]([CH:25]3[CH2:26][CH2:27][O:28][CH2:29][CH2:30]3)[C:22]([CH3:24])=[N:23][C:19]=2[CH:18]=1참가 물질
3
실험 절차
5-(N-t-butoxycarbonylindol-2-yl)-2-methyl-1-(tetrahydropyran-4-yl)benzimidazole (see Synthesis Example 37 (200 mg, 0.463 mmol) was added to a 1N aqueous hydrochloric acid solution (10 mL), and this was stirred at room temperature for 3 hours. After the reaction was complete, this was allowed to stand for 3 days and the precipitated crystals were filtered off, and to this was added saturated aqueous sodium hydrogen carbonate (5 mL) and this was stirred for 30 minutes. The precipitated crystals were filtered off, washed with water and dried to yield the title compound (155 mg, quant.) as light brown crystals.